CORRECTION: Nurix Therapeutics Q3 EPS $4.73 Beats $3.98 Estimate, Sales $673.064M Beat $411.481M Estimate

Nurix Therapeutics (NASDAQ: NRIX) reported Q3 earnings of $4.73 per share, exceeding the analyst estimate of $3.98 by 18.84%, and representing a 559.22% increase from a loss of $(1.03) per share in the same period last year. The company also reported quarterly sales of $673.064 million, surpassing the consensus estimate of $411.481 million by 63.57%, and showing an 8.43K% increase from $7.894 million in the prior year.